title: [Chances and risks of blood-based molecular pathological analysis of circulating tumor cells (CTC) and cell-free DNA (cfDNA) in personalized cancer therapy: positional paper from the study group on liquid biopsy of the working group for molecular pathology in the German Society of Pathology (DGP)].
authors.affiliation: Institut für Pathologie, Uniklinik RWTH Aachen, Aachen, Deutschland, edahl@ukaachen.de.
authors.forename: E
authors.initials: E
authors.lastname: Dahl
authors.forename: A
authors.initials: A
authors.lastname: Jung
authors.forename: J
authors.initials: J
authors.lastname: Fassunke
authors.forename: M
authors.initials: M
authors.lastname: Hummel
authors.forename: R
authors.initials: R
authors.lastname: Penzel
authors.forename: W
authors.initials: W
authors.lastname: Dietmaier
authors.forename: S
authors.initials: S
authors.lastname: Laßmann
mesh_terms: D001706:Biopsy; D002474:Cell-Free System / Q000473:pathology*; D004273:DNA, Neoplasm / Q000235:genetics*; D006801:Humans; D025202:Molecular Diagnostic Techniques; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D009360:Neoplastic Cells, Circulating / Q000378:metabolism* / Q000473:pathology; D057285:Precision Medicine / Q000379:methods*; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors; D047368:Tumor Burden
chemical_list: D004273:DNA, Neoplasm